Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057874 · ClinicalTrials.gov registry record · NA
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02057874: Clinical Trial NA study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT02057874 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02057874, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Compared to conventional imaging, multi-parametric 3-Tesla MRI offers the ability to quantitatively measure tissue structural, functional, cellular, and molecular properties, providing a more robust, clinically relevant method for assessing cancer response to therapy.
Primary Outcome
The following will be longitudinally measured using 3 Tesla (3T) magnetic resonance imaging (MRI) prior to transarterial chemoembolization (TACE) and 2-4, 4-8, and 12 weeks following TACE: 1) the volume transfer coefficient (Ktrans), measured by dynamic contrast-enhanced (DCE) MRI; 2) the apparent diffusion coefficient (ADC), measured by diffusion-weighted (DW) MRI; 3) the magnetization transfer ratio (MTR), measured by magnetization transfer (MT) MRI; and 4) the amide proton transfer asymmetry
Interventions
- DEVICE 3 Tesla Magnetic Resonance Imaging
- DRUG Magnevist® (Intravenous (IV) administration of MRI contrast agent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12-04 |
| Phase | NA |
Why NCT02057874 stopped before completion
NCT02057874 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which 3 Tesla Magnetic Resonance Imaging is the first listed.
NCT02057874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02057874 about?
NCT02057874 is a clinical study titled "3-Tesla MRI Response to TACE in HCC (Liver Cancer)". This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Compared to conventional imaging, mu...
What is the current status of trial NCT02057874?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2014-02. Estimated completion is 2015-12-04.
What interventions are being tested in trial NCT02057874?
The interventions under investigation include: 3 Tesla Magnetic Resonance Imaging (DEVICE), Magnevist® (Intravenous (IV) administration of MRI contrast agent) (DRUG).
Who is sponsoring clinical trial NCT02057874?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02057874's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia